| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | MTND3; ND3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human MT-ND3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ENPP3抗体的3篇代表性文献(文献信息为示例，建议通过学术数据库查询最新研究)：
1. **标题**：ENPP3 as a target for antibody-based therapy in renal cell carcinoma
**作者**：Thompson MA et al.
**摘要**：研究证明ENPP3在肾细胞癌中高表达，开发了一种靶向ENPP3的单克隆抗体，体外和小鼠模型中显示可通过抗体依赖性细胞毒性(ADCC)抑制肿瘤生长。
2. **标题**：ENPP3/CD203c expression in mast cell disorders: A diagnostic and therapeutic biomarker
**作者**：Krauth MT et al.
**摘要**：探讨ENPP3(CD203c)抗体在肥大细胞疾病中的诊断价值，发现其高表达与疾病进展相关，提示其可作为靶向治疗的生物标志物。
3. **标题**：Development of a novel anti-ENPP3 antibody-drug conjugate for pancreatic cancer therapy
**作者**：Suzuki Y et al.
**摘要**：报道了一种新型ENPP3抗体-药物偶联物(ADC)，在胰腺癌模型中通过靶向递送细胞毒性药物显著抑制肿瘤，验证了ENPP3作为实体瘤治疗靶点的潜力。
建议通过PubMed或Google Scholar搜索关键词“ENPP3 antibody”或“CD203c therapeutic”获取最新研究进展。
ENPP3 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 3), also known as CD203c, is a transmembrane glycoprotein belonging to the nucleotide pyrophosphatase/phosphodiesterase family. It hydrolyzes extracellular nucleotides like ATP and ADP, regulating purinergic signaling pathways involved in cellular processes such as proliferation, differentiation, and immune responses. ENPP3 is physiologically expressed in specific tissues, including the kidney, gastrointestinal tract, and mast cells/basophils, where it serves as an activation marker.
In pathology, ENPP3 has gained attention for its overexpression in certain cancers, notably renal cell carcinoma (RCC), pancreatic neuroendocrine tumors, and some adenocarcinomas. This overexpression correlates with tumor progression, metastasis, and poor prognosis, making ENPP3 a potential therapeutic target. ENPP3-targeting antibodies, particularly monoclonal antibodies (mAbs), are being explored for diagnostic and therapeutic applications. For example, antibody-drug conjugates (ADCs) like SC-004 (an anti-ENPP3 ADC) have shown preclinical efficacy in RCC models by delivering cytotoxic payloads directly to tumor cells.
Diagnostically, ENPP3 antibodies are used in immunohistochemistry (IHC) or flow cytometry to detect ENPP3 expression in cancer biopsies or hematologic samples, aiding in disease stratification. Research also suggests roles in allergic responses, as ENPP3 on basophils is upregulated during IgE-mediated activation. Despite promising data, clinical validation is ongoing to optimize specificity and minimize off-target effects. Overall, ENPP3 antibodies represent a dual-purpose tool bridging cancer research, targeted therapy, and diagnostic innovation.
×
